Cavtat-Dubrovnik, Croatia
More info
News & events
Innate Pharma SA announces today its financial results for the first half of 2010.
August 31, 2010
The key financial elements for the half-year results are as follows :
- Programs on track
- Decrease in operating loss
- Controlled burn rate and strong cash position
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
July 21, 2010
Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at June 30, 2010:
- 108,104 shares of Innate Pharma, and
- 51,728.95 euros in cash.
For information, the following assets appeared on the liquidity account at the latest report:
- 69,741 shares of Innate Pharma, and
- 121,955.05 euros in cash.
Final data on response rate for the Phase II trial with IPH 1101 in Follicular Lymphoma reported at the EHA meeting
June 13, 2010
- Favorable complete response rate with IPH 1101 associated with low-dose IL-2 in combination with rituximab
- Last trial of the clinical program for IPH 1101 completed in a context where new cancer immunotherapies are emerging
- In total, the drug candidate was administered to about 200 patients in six clinical trials with good safety and early signs of activity in HCV and NHL
Innate Pharma announces its participation to major upcoming medical meetings
June 3, 2010
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will report clinical data for its two lead clinical drug candidate at the following June’s medical meetings: EHA and ASCO
Innate Pharma announces the outcome of its annual general meeting, as well as changes in the composition of its management and governance bodies
May 26, 2010
Quorum above 70%; all proposed resolutions were voted according to management’s recommendations.
Innate Pharma releases its total number of shares outstanding as well as its voting rights as at April 30, 2010
May 10, 2010
Innate Pharma releases its total number of shares outstanding as well as its voting rights as at April 30, 2010:
Total number of shares outstanding:37,686,794
Total number of theoretical voting rights (1):37,686,794
Total number of exercisable voting rights (2):37,598,258